Rocket Pharma (RCKT) GC sale covers taxes on RSU vesting

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. (RCKT) reported that General Counsel Martin Wilson sold 631 shares of common stock on 2026-08-18 at $3.381 per share. According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units. After this transaction, Wilson directly holds 673,853 shares, including RSUs that convert to common stock on a one-for-one basis.

Insider Trade Summary

Net Seller: 631 shares

Net Sell 1 txn

Insider Wilson Martin

Role General Counsel

Sold 631 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	631	$3.381	$2K

Holdings After Transaction: Common Stock — 673,853 shares (Direct)

Footnotes (2)

1. F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. F2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Key Figures

Shares sold: 631 shares Sale price per share: $3.381 per share Shares held after transaction: 673,853 shares

3 metrics

Shares sold 631 shares Common Stock sold on 2026-08-18

Sale price per share $3.381 per share Price for the 631 shares sold on 2026-08-18

Shares held after transaction 673,853 shares Direct holdings after the 631-share sale; includes RSUs

Key Terms

Restricted Stock Units, RSUs, tax withholding obligations, vesting

4 terms

Restricted Stock Units financial

"Holdings include Restricted Stock Units ("RSUs") that convert to common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"RSUs that convert to common stock on a one-for-one basis"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"sold by the Reporting Person in order to pay tax withholding obligations"

vesting financial

"tax withholding obligations in connection with the vesting of RSUs"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transaction did RCKT report for Martin Wilson?

RCKT reported that General Counsel Martin Wilson sold 631 shares of common stock on 2026-08-18 at $3.381 per share, in a transaction designated as a sale in the open market or a private transaction.

Why did Martin Wilson sell Rocket Pharmaceuticals (RCKT) shares?

The company states that the 631 shares of common stock were sold by Martin Wilson to pay tax withholding obligations in connection with the vesting of RSUs (Restricted Stock Units).

How many RCKT shares does Martin Wilson hold after the reported sale?

After the sale, Martin Wilson directly holds 673,853 shares of Rocket Pharmaceuticals common stock. The company notes that these holdings include RSUs that convert to common stock on a one-for-one basis.

What was the sale price for the Rocket Pharmaceuticals (RCKT) insider transaction?

The reported sale price was $3.381 per share for the 631 shares of Rocket Pharmaceuticals common stock sold by Martin Wilson on 2026-08-18.

Does the RCKT filing mention a Rule 10b5-1 trading plan?

The filing indicates that the Rule 10b5-1 checkbox is false, and there is no footnote stating that the 631-share sale was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 05:30 PM Accepted by SEC EDGAR 08/20/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Martin

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	08/18/2026		S(2)		631	D	$3.381	673,853(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

	/s/ Martin Louis Wilson	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)